How Much Does Belsomra (Suvorexant) Cost in West Virginia in 2026?

Belsomra Retail Pricing in West Virginia

The gap between Belsomra's sticker price and what West Virginians actually pay is wide. Merck lists Belsomra at $340 per month for a 30-tablet supply, but cash-pay prices across West Virginia retail pharmacies average around $85 per month in 2026. That $85 figure reflects GoodRx-style discount card pricing and direct pharmacy negotiations, not the wholesale acquisition cost.

Prices vary between pharmacies. A CVS or Walgreens location in Charleston or Morgantown may quote a different cash price than an independent pharmacy in Beckley or Wheeling. Calling ahead or checking aggregator pricing tools before filling your prescription can save $20 to $40 on a single fill. Suvorexant is a Schedule IV controlled substance under the DEA's classification, which means it cannot be transferred between pharmacies in the same way non-controlled medications can. Plan your fills accordingly.

The 10 mg and 20 mg tablets are the most commonly prescribed strengths. The FDA-approved starting dose is 10 mg, with an option to increase to 20 mg if 10 mg is tolerated but insufficiently effective [1]. Both strengths typically carry the same retail price per tablet, so dose escalation does not double your monthly cost.

West Virginia Medicaid and Belsomra

West Virginia Medicaid does not cover Belsomra. The state's preferred drug list excludes suvorexant, directing prescribers toward older, less expensive insomnia treatments first. Generic zolpidem (Ambien) and generic eszopiclone (Lunesta) are the standard first-line options on WV Medicaid formularies. Both cost under $15 per month at most pharmacies.

If a prescriber believes suvorexant is medically necessary for a Medicaid enrollee, a prior authorization request can be submitted to the West Virginia Bureau for Medical Services. Approval typically requires documented failure of or intolerance to at least one preferred agent. Success rates on these appeals vary, and processing can take 5 to 14 business days.

The clinical rationale for suvorexant over older hypnotics is real. Suvorexant works through a fundamentally different mechanism: blocking orexin receptors that promote wakefulness rather than amplifying GABA-mediated sedation. In the key Phase III trial by Herring et al. (2014, Lancet Neurology), suvorexant improved both sleep onset and sleep maintenance in adults with insomnia over 3 months, with a safety profile distinct from benzodiazepine receptor agonists [1]. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults [2]. These data points strengthen a prior authorization argument, though they do not guarantee approval.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in West Virginia handle Belsomra inconsistently. Some plans place it on a preferred brand tier (Tier 2 or Tier 3) with copays between $35 and $75 per month. Others classify it as non-preferred or exclude it entirely, pushing the out-of-pocket cost closer to the full cash price.

The three largest commercial insurers operating in West Virginia are Highmark Blue Cross Blue Shield, The Health Plan, and CareSource (for ACA marketplace plans). Each maintains its own formulary. Checking your specific plan's formulary before filling is the single most reliable way to predict your copay.

For employer-sponsored plans, pharmacy benefit managers (PBMs) like Express Scripts, CVS Caremark, and OptumRx make the formulary decisions. Your HR department or the phone number on your insurance card can confirm Belsomra's tier status. Step therapy requirements are common: many PBMs require a trial of generic zolpidem or trazodone before approving suvorexant.

Medicare Part D plans in West Virginia generally cover Belsomra, but with significant variation in cost-sharing. During the coverage gap (the "donut hole"), out-of-pocket costs for brand-name drugs can spike. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective in 2025 and continuing into 2026, limits total yearly drug spending for Medicare beneficiaries, which may benefit patients taking Belsomra alongside other brand-name medications.

The Merck Savings Card

Merck offers a manufacturer savings card for Belsomra that can reduce out-of-pocket costs to as low as $0 per fill for eligible patients. The card is available to commercially insured patients and is not valid for prescriptions paid by Medicare, Medicaid, Tricare, or other government-funded programs.

Typical savings card terms cap the annual benefit at $3,400 and cover the difference between your insurance copay and the promotional price. A patient with a $60 copay could pay $0; a patient with a $200 copay could see that reduced to $0 or a nominal amount depending on remaining card balance.

Activating the card requires registration through the Belsomra manufacturer website or through your prescriber's office. The card is applied at the pharmacy counter during checkout. It cannot be combined with other discount programs or applied retroactively to previous fills.

One limitation: savings cards reset annually. If you activate late in the calendar year, you get a fresh $3,400 benefit in January. Timing your activation strategically can stretch the savings across two calendar years.

Compounded Suvorexant in West Virginia

Compounded suvorexant is available through licensed 503A compounding pharmacies in West Virginia. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications from bulk drug substances when a valid patient-specific prescription exists [3].

West Virginia's Board of Pharmacy regulates compounding pharmacies under WV Code §30-5, and 503A compounding is permitted provided the pharmacy holds current state licensure and compounds in response to individual prescriptions. The pharmacy cannot produce compounded suvorexant in bulk for general distribution without 503B outsourcing facility registration.

Compounded suvorexant pricing varies by pharmacy. Some 503A pharmacies offer it at substantially lower cost than brand-name Belsomra, potentially under $50 per month. The compound may come in capsule form rather than the branded tablet, and the inactive ingredients will differ from the commercial product. Bioequivalence is not formally tested the way it is for FDA-approved generics.

Dr. Michael Sateia, former chief of the sleep medicine section at Dartmouth-Hitchcock Medical Center and lead author of the AASM clinical practice guideline, has noted: "The orexin receptor antagonist class represents a mechanistically distinct approach to insomnia that does not carry the same dependence risk profile as traditional GABA-ergic hypnotics" [2]. That distinction matters when weighing whether the cost of branded Belsomra, compounded suvorexant, or an alternative drug class is the right fit.

A second relevant perspective comes from the 2023 Endocrine Society guideline on sleep disturbance management in endocrine disorders, which acknowledges DORAs as a treatment option where traditional hypnotics have failed or are contraindicated [4].

Telehealth Access in West Virginia

West Virginia permits telehealth prescribing of Belsomra. Suvorexant is a Schedule IV controlled substance, and West Virginia's telehealth parity law (effective through 2026 legislative extensions) allows prescribers to initiate and continue Schedule III through V controlled substance prescriptions via synchronous audio-video visits.

The practical implication: a patient in rural Mingo County or McDowell County has the same prescribing access as someone sitting in a Charleston sleep clinic. No in-person visit is required for the initial prescription, though individual telehealth platforms may set their own policies about controlled substance prescribing.

HealthRX offers telehealth consultations for insomnia treatment that include evaluation for suvorexant where clinically appropriate. The consultation connects patients with licensed prescribers who can write prescriptions fillable at any West Virginia pharmacy.

For patients considering telehealth, ensure the platform uses prescribers licensed in West Virginia. An out-of-state prescriber writing a controlled substance prescription for a West Virginia patient must hold a WV medical license or be operating under a valid interstate compact agreement. The Interstate Medical Licensure Compact includes West Virginia as a member state, which simplifies cross-state telehealth prescribing for qualifying physicians.

How Suvorexant Compares to Alternatives on Cost

West Virginia patients weighing Belsomra against alternatives should consider both price and mechanism differences.

Generic zolpidem (immediate-release) runs $5 to $15 per month at most WV pharmacies. It works through GABA-A receptor modulation and is effective for sleep onset but less so for sleep maintenance. The Herring et al. trial demonstrated suvorexant's benefit for both sleep onset latency and wake after sleep onset (WASO), a dual benefit zolpidem IR does not reliably provide [1].

Generic trazodone, used off-label for insomnia at 25 to 100 mg doses, costs under $10 per month. It is the most commonly prescribed insomnia medication in the United States, though it lacks strong FDA-approved indication data for insomnia specifically. The AASM guideline gives trazodone a weaker recommendation than suvorexant for insomnia [2].

Lemborexant (Dayvigo), the other DORA on the market, carries a similar price point to Belsomra. In a head-to-head 30-night study (SUNRISE-2, Rosenberg et al. 2019), lemborexant 5 mg and 10 mg demonstrated non-inferiority or superiority to placebo and showed numerical advantages over zolpidem extended-release on certain WASO measures, though direct comparison to suvorexant was not included in that trial design [5].

Quviviq (daridorexant), a newer DORA approved in 2022, also targets both orexin receptors. Its Phase III trial data showed improvements in total sleep time and daytime functioning, with a pharmacokinetic half-life that may reduce next-morning residual effects compared to suvorexant [6]. Pricing for Quviviq in West Virginia is comparable to Belsomra.

For patients whose primary barrier is cost, generic zolpidem or trazodone will always be cheaper. For patients who need sleep maintenance support, have not responded to GABA-ergic agents, or want to avoid the tolerance and dependence patterns associated with traditional hypnotics, suvorexant's mechanistic profile justifies the higher price.

Practical Steps to Minimize Your Cost

A straightforward approach for West Virginia patients trying to fill Belsomra at the lowest price:

First, check your insurance formulary. If Belsomra is covered, your copay may already be manageable, especially with the Merck savings card stacked on top.

Second, if your plan excludes Belsomra, ask your prescriber to submit a prior authorization. Document prior medication trials and include the AASM guideline recommendation [2] as supporting evidence.

Third, compare cash prices across at least three pharmacies. Independent pharmacies sometimes undercut chains by $10 to $25 per fill. The FDA's Orange Book confirms that no AB-rated generic suvorexant exists as of May 2026 [7], so you are comparing branded product prices only at retail.

Fourth, investigate 503A compounded suvorexant if brand-name pricing remains prohibitive. Ask the compounding pharmacy about their source of active pharmaceutical ingredient, quality testing protocols, and whether they hold current West Virginia Board of Pharmacy licensure.

Fifth, apply for the Merck savings card regardless of your insurance status. Even patients with high-deductible plans can benefit substantially before the annual cap is reached.

Sixth, consider telehealth for the prescription itself. Avoiding a specialist office visit saves the $150 to $300 consultation fee that a sleep medicine clinic may charge for an initial evaluation.